3种方案治疗幽门螺杆菌感染的成本效果分析

Pharmacoeconomical analysis of three therapeutic regimens for Helicobacter pylori infection

目的:对幽门螺杆菌(Hp)感染的3种药物治疗方案进行药物经济学评价。方法:A组用兰索拉唑30mg+呋喃唑酮100 mg+克拉霉素250 mg,bid×7d+兰索拉唑30 mg,qd×14 d;B组用雷贝拉唑10 mg+呋喃唑酮100mg+克拉霉素250 mg,bid×7 d+雷贝拉唑10 mg,qd×14 d;C组用奥美拉唑20 mg+呋喃唑酮100 mg+克拉霉素250mg,bid×7 d+奥美拉唑20 mg,qd×14 d。用成本效果分析法对3种方案进行分析。结果:A,B,C 3种方案的成本效果比(C/E)分别为18.60,20.04,16.30。结论:方案C是3种方案中最经济、合理的方案。

Objective： To evaluate the pharmacoeconomical outcome of three therapeutic regimens for Helicobacter pylori infection. Methods： Three therapeutic regimens for Helicobacter pylori infection were compared by a cost-effectiveness analysis. These regimens were composed of lansoprazole 30 mg ＋ furazolidone 100 mg ＋ clarithromycin 250 mg, bid, for 7 days and then lansoprazole 30 mg, qd, for 14 days （scheme A） ; rabeprazole 10 mg ＋ furazolidone 100 mg ＋ clarithromycin 250 mg,bid, for 7 days and then rabeprazole 10 mg, qd, for 14 days （scheme B） ; and omeprazole 20 mg ＋ furazolidone 100 mg ＋ clarithromycin 250 mg, bid, for 7 days and then omeprazole 20 mg, qd, for 14 days （scheme C）. Results：The cost effectiveness ratio of three regimens was 18.60, 20.04 and 16.30, respectively. Conclusion： The scheme 3 was considered the best regimen in the viewpoint of pharmacoeconomics.